Top in rheumatology: Barriers to paid family leave; risks of B-cell depleting therapies
Click Here to Manage Email Alerts
The standard 12 weeks of paid family leave in the United States is often unavailable to health care providers. For them, the reality of paid leave is much different, experts said.
The stigma and obstacles that nurses and physicians face when trying to take paid family leave can be difficult to overcome. It was the top story in rheumatology last week.
Another top story covered the association of B-cell depleting agents with reduced antibody responses to SARS-CoV-2 vaccination.
Read these and more top stories in rheumatology below:
Health care industry struggles to keep pace with ‘tectonic shift’ in paid family leave
For a growing number of Americans, 12 weeks of paid leave from work after the birth of a child, or to care for an ailing family member, is standard. For many health care providers, including physicians and nurses, the reality of paid leave is much different. Read more.
B-cell depleting therapies ‘biggest threat’ for reduced SARS-CoV-2 mRNA vaccine response
B-cell depleting agents, glucocorticoids and mycophenolate mofetil have all been associated with reduced antibody responses to SARS-CoV-2 vaccination, noted a presenter at the 2022 Association of Women in Rheumatology Annual Conference. Read more.
FDA approves citrate-free, high concentration formulation of Humira biosimilar
The FDA has approved a citrate-free, 100 mg/mL formulation of the Humira biosimilar Hadlima, according to a statement released by Samsung Bioepis and Organon. Read more.
Immune-related adverse events present ‘double-edged sword,’ need multidisciplinary input
Although oncologists take the lead in cancer management with immunotherapies, rheumatologist input is essential to managing the ensuing immune-related adverse events, which pose challenges to coordinated patient care. Read more.
‘Comfort level’ driving divide between rheumatologists, nephrologists in lupus nephritis
Recent data has revealed a growing divide between rheumatologists and nephrologists in their therapeutic choices for patients with lupus nephritis, according to researchers from Spherix Global Insights. Read more.